GGrantIndex
← Search

GALACTOSE METABOLIC PATHWAYS

$293,069M01FY2002RRNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Abstract

The overall hypothesis is that enigmatic clinical outcomes in patients with galactosemia who have identical molecular and biochemical mutations in red blood cell galactose-1-phosphate uridyltransferase (GALT) are caused by alternative pathways and organ-specific impairment for galactose metabolism. This hypothesis will be tested by quantitative and qualitative comparisons of in vivo galactose metabolic pathways in patients with galactosemia who are homozygous for the Q188R mutation, and have other defined mutations.

View original record on NIH RePORTER →